1398PReal-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC). (23rd October 2018) - Jahanzeb, M; Lin, H M; Pan, X; Yin, Y; Hou, P; Nordstrom, B L; Desai, A; Socinski, M A